Barri 4
Generic Name: Baricitinib 4 mg
Dosage Form: Tablet
TG Name: Musculoskeletal
1. What is Barri® 4?
Barri® 4 is a formulation of Baricitinib 4 mg which is a selective and reversible inhibitor of Janus kinase (JAK1 and JAK2).
2. How Barri® 4 works in our body?
Baricitinib inhibits the activities of JAK1, JAK2, Tyrosine Kinase 2 and JAK3. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function.
3. What is the indication of Barri® 4?
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the use of Baricitinib, in combination with remdesivir, for treatment of suspected or laboratory confirmed Coronavirus disease 2019 (COVID-19) hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
4. What are the dosage & administration of Barri® 4?
Baricitinib 4 mg once daily (orally) for 14 days or until hospital discharge. Baricitinib is given orally with or without food. For patients who are unable to swallow whole tablets, alternate administration may be considered:
- a) Oral dispersion
- b) Gastrostomy tube (G tube)
- c) Nasogastric tube (NG tube)
5. What are the contraindications of Barri® 4?
There are no known contraindications for Baricitinib.
6. What are the adverse effects of Barri® 4?
Serious venous thrombosis, including pulmonary embolism, and serious infections have been observed in COVID-19 patients treated with Baricitinib and are known adverse drug reactions of Baricitinib.
7. What would be the storage condition of Barri® 4?
Keep in a dry place, below 30o C. Protect from light. Keep out of the reach of children.
